Search

Your search keyword '"Zigon, Polona"' showing total 17 results
Start Over Author "Zigon, Polona"
17 results on '"Zigon, Polona"'

6. List of Contributors

Author

Abu-Shakra, Mahmoud, primary, Alard, Jean-Eric, additional, Amital, Howard, additional, Andreoli, L., additional, Antico, Antonio, additional, Antonelli, Alessandro, additional, Aoki, Christopher A., additional, Arepally, Gowthami, additional, Asashima, Hiromitsu, additional, Atzeni, Fabiola, additional, Bagnasco, Marcello, additional, Barcellini, Wilma, additional, Bayry, Jagadeesh, additional, Bendtzen, Klaus, additional, Ben-Nun, Avraham, additional, Berden, Jo H.M., additional, Bernareggi, Davide, additional, Bertolaccini, Maria Laura, additional, Bizzaro, Nicola, additional, Bogdanos, Dimitrios, additional, Borghi, Maria O., additional, Bowlus, Christopher L., additional, Božič, Borut, additional, Calise, S. John, additional, Caneparo, Valeria, additional, Canevari, Silvana, additional, Carcamo, Wendy C., additional, Carp, Howard J.A., additional, Cavazzana, Ilaria, additional, Ceribelli, Angela, additional, Cervera, Ricard, additional, Chan, Edward K.L., additional, Chan, Happy, additional, Chan, Jason Y.F., additional, Chang, Christopher, additional, Chapple, Katie, additional, Chiang, Bor-Luen, additional, Chighizola, Cecilia B., additional, Christen, Urs, additional, Ciavarella, Teresa, additional, Cicardi, Marco, additional, Cines, Douglas B., additional, Eschler, Deirdre Cocks, additional, Conrad, Karsten, additional, Coutinho, Ester, additional, Crotti, Chiara, additional, Csernok, Elena, additional, Čuc čnik, Sasa, additional, Cugno, Massimo, additional, Cuker, Adam, additional, Czarnocka, Barbara, additional, de Andrea, Marco, additional, Dell’Oste, Valentina, additional, De Los Reyes Labitigan, Monalyn, additional, Dominguez, Yasmany, additional, Einav, Yulia, additional, Fallahi, Poupack, additional, Feist, Eugen, additional, Ferri, Clodoveo, additional, Figini, Mariangela, additional, Fisher, Benjamin A., additional, Franceschini, Franco, additional, Fredi, M., additional, Fritzler, Marvin J., additional, Gariglio, Marisa, additional, Gerosa, Maria, additional, Gershwin, M. Eric, additional, Giometto, Bruno, additional, Giuggioli, Dilia, additional, Godlewska, Marlena, additional, Gross, Wolfgang L., additional, Grossman, Chagai, additional, Gualtierotti, Roberta, additional, Hamann, Dörte, additional, Harel, Michal, additional, Hershko, Alon Y., additional, Hiepe, Falk, additional, Hodak, Emmilia, additional, Huda, Saif, additional, Hultman, Per, additional, Iizuka, Mana, additional, Invernizzi, Pietro, additional, Jamin, Christophe, additional, Juan, Manel, additional, Kallenberg, Cees G.M., additional, Kapsogeorgou, Efstathia K., additional, Karussis, Dimitrios, additional, Kaushansky, Nathali, additional, Kaveri, Srini V., additional, Kawakita, Satoru, additional, Kazatchkine, Michel D., additional, Khamashta, Munther A., additional, Khan, Farah, additional, Küpper, Jan-Heiner, additional, Kveder, Tanja, additional, Lacroix-Desmazes, Sébastien, additional, Lakota, Katja, additional, Landolfo, Santo, additional, Lang, Bethan, additional, Lazúrová, Ivica, additional, Le Meur, Yannick, additional, Lerner, Aaron, additional, Li, Yi, additional, Liberal, Rodrigo, additional, Lidar, Merav, additional, Linington, Christopher, additional, Lima, Breno R., additional, Lleo, Ana, additional, Lopez, Luis R., additional, Maddison, Paul, additional, Mahler, Michael, additional, Matsumoto, Isao, additional, Matsuura, Eiji, additional, Meroni, Pier Luigi, additional, Mieli-Vergani, Giorgina, additional, Mimouni, Daniel, additional, Mrak-Poljsak, Katjusa, additional, Muller, Sylviane, additional, Muratori, Luigi, additional, Naguwa, Stanley M., additional, Naparstek, Yaakov, additional, Nobile-Orazio, Eduardo, additional, Nussenblatt, Robert B., additional, Pasvolsky, Oren, additional, Patil, Veerupaxagouda, additional, Paz, Damien Luque, additional, Paz, Ziv, additional, Pelizza, Federica, additional, Penatti, Alessandra, additional, Pengo, Vittorio, additional, Perricone, Carlo, additional, Perricone, Roberto, additional, Pers, Jacques-Olivier, additional, Petríková, Jana, additional, Petrou, Panayiota, additional, Piantoni, S., additional, Pietropaolo, Massimo, additional, Pittock, Sean J., additional, Pollard, K. Michael, additional, Pregnolato, Francesca, additional, Pura, Mikuláš, additional, Putterman, Chaim, additional, Radice, Antonella, additional, Raschi, Elena, additional, Ravindranath, Mepur H., additional, Reeves, Westley H., additional, Renaudineau, Yves, additional, Rinaldi, Maurizio, additional, Roggenbuck, Dirk, additional, Ronda, Nicoletta, additional, Rose, Noel R., additional, Rosenberg, Nurit, additional, Rozman, Blaž, additional, Ruffatti, Amelia, additional, Sarzi-Puttini, Piercarlo, additional, Satoh, Minoru, additional, Sciascia, Savino, additional, Scofield, R. Hal, additional, Sebastiani, Marco, additional, Selmi, Carlo, additional, Nida Sen, H., additional, Shenkman, Boris, additional, Shoenfeld, Yehuda, additional, Sinico, Renato Alberto, additional, Smeenk, Ruud J.T., additional, Sodin-Semrl, Snezna, additional, Sperling, Mark A., additional, Steenholdt, Casper, additional, Stöcker, Winfried, additional, Strassburg, Christian P., additional, Suffritti, Chiara, additional, Sumida, Takayuki, additional, Tampoia, Marilina, additional, Tedeschi, Alberto, additional, Tedesco, Francesco, additional, Terasaki, Paul I., additional, Tincani, Angela, additional, Tomer, Yaron, additional, Tonutti, Elio, additional, Toothaker, Thomas B., additional, Tozzoli, Renato, additional, Tsokos, George C., additional, Tsuboi, Hiroto, additional, Tzioufas, Athanasios G., additional, Ulmansky, Rina, additional, Usuki, Seigo, additional, Vaknin-Dembinsky, Adi, additional, van der Vlag, Johan, additional, Vergani, Diego, additional, Villalta, Danilo, additional, Vincent, Angela, additional, Weiner, Maya Ram, additional, Wener, Mark H., additional, Wiik, Allan, additional, Witte, Torsten, additional, Yang, Li-Jun, additional, Yang, Yao-Hsu, additional, Youinou, Pierre, additional, Yu, Hsin-Hui, additional, Yu, Robert K., additional, Zandman-Goddard, Gisele, additional, Zanella, Alberto, additional, Zanichelli, Andrea, additional, Zavdy, Ofir, additional, Zhuang, Haoyang, additional, and Zigon, Polona, additional

Published
2014
Full Text
View/download PDF

8. Obstetrical outcome and treatments in seronegative primary APS : data from European retrospective study

Author

Abisror, Noemie, Nguyen, Yann, Marozio, Luca, Esteve Valverde, Enrique, Udry, Sebastian, Pleguezuelo, Daniel Enrique, Billoir, Paul, Mayer-Pickel, Karoline, Urbanski, Geoffrey, Zigon, Polona, De Moreuil, Claire, Hoxha, Ariela, Bezanahary, Holy, Carbillon, Lionel, Kayem, Gilles, Bornes, Marie, Yelnik, Cecile, Johanet, Cathererine, Nicaise-Roland, Pascale, Lambert, Marc, Salle, Valéry, Latino, Omar Jose, Hachulla, Eric, Benedetto, Chiara, Bourrienne, Marie Charlotte, Benhamou, Ygal, Alijotas-Reig, Jaume, Fain, Olivier, Mekinian, Arsène, Abisror, Noemie, Nguyen, Yann, Marozio, Luca, Esteve Valverde, Enrique, Udry, Sebastian, Pleguezuelo, Daniel Enrique, Billoir, Paul, Mayer-Pickel, Karoline, Urbanski, Geoffrey, Zigon, Polona, De Moreuil, Claire, Hoxha, Ariela, Bezanahary, Holy, Carbillon, Lionel, Kayem, Gilles, Bornes, Marie, Yelnik, Cecile, Johanet, Cathererine, Nicaise-Roland, Pascale, Lambert, Marc, Salle, Valéry, Latino, Omar Jose, Hachulla, Eric, Benedetto, Chiara, Bourrienne, Marie Charlotte, Benhamou, Ygal, Alijotas-Reig, Jaume, Fain, Olivier, and Mekinian, Arsène

Abstract

To compare characteristics, pregnancies and treatments during pregnancies of seronegative and seropositive antiphospholipid syndrome (APS), to analyse factors associated with obstetrical outcome. Inclusion criteria were: (1) thrombotic and/or obstetrical APS (Sydney criteria); (2) absence of conventional antiphospholipid antibodies (APL); (3) at least one persistent non-conventional APL among IgA anticardiolipin antibodies, IgA anti-B2GPI, anti-vimentin G/M, anti-annexin V G/M, anti-phosphatidylethanolamine G/M and anti-phosphatidylserine/prothrombin G/M antibodies. The exclusion criteria were: (1) systemic lupus erythematosus (SLE) or SLE-like disease; and (2) other connective tissue disease. A total of 187 women (mean 33±5 years) with seronegative APS were included from 14 centres in Austria, Spain, Italy, Slovenia and France and compared with 285 patients with seropositive APS. Seronegative APS has more obstetrical rather than thrombotic phenotypes, with only 6% of venous thrombosis in comparison to seropositive APS. Cumulative incidence of adverse obstetrical events was similar in seronegative and seropositive APS patients, although higher rates of intrauterine deaths (15% vs 5%; p=0.03), of preeclampsia (7% vs 16%, p=0.048) and lower live birth term (36±3 vs 38±3 weeks of gestation; p=0.04) were noted in seropositive APS. The cumulative incidence of adverse obstetrical events was significantly improved in treated versus untreated seronegative APS (log rank<0.05), whereas there was no difference between patients who received aspirin or aspirin-low-molecular weighted heparin combination. Several non-criteria APL can be detected in patients with clinical APS features without any conventional APL, with various rates. The detection of non-criteria APL and thus the diagnosis of seronegative APS could discuss the therapeutic management similar to seropositive APS, but well-designed controlled studies are necessary

Published
2020

10. Olive Leaf Extract Attenuates Inflammatory Activation and DNA Damage in Human Arterial Endothelial Cells

Author

Burja, Blaz, Burja, Blaz, Kuret, Tadeja, Janko, Tea, Topalović, Dijana, Živković, Lada, Mrak-Poljsak, Katjusa, Potparević, Biljana, Zigon, Polona, Distler, Oliver, Cucnik, Sasa, Sodin-Semrl, Snezna, Lakota, Katja, Frank-Bertoncelj, Mojca, Burja, Blaz, Burja, Blaz, Kuret, Tadeja, Janko, Tea, Topalović, Dijana, Živković, Lada, Mrak-Poljsak, Katjusa, Potparević, Biljana, Zigon, Polona, Distler, Oliver, Cucnik, Sasa, Sodin-Semrl, Snezna, Lakota, Katja, and Frank-Bertoncelj, Mojca

Abstract

Olive leaf extract (OLE) is used in traditional medicine as a food supplement and as an over-the-counter drug for a variety of its effects, including anti-inflammatory and anti-atherosclerotic ones. Mechanisms through which OLE could modulate these pathways in human vasculature remain largely unknown. Serum amyloid A (SAA) plays a causal role in atherosclerosis and cardiovascular diseases and induces pro-inflammatory and pro-adhesive responses in human coronary artery endothelial cells (HCAEC). Within this study we explored whether OLE can attenuate SAA-driven responses in HCAEC. HCAEC were treated with SAA (1,000 nM) and/or OLE (0.5 and 1 mg/ml). The expression of adhesion molecules VCAM-1 and E-selectin, matrix metalloproteinases (MMP2 and MMP9) and microRNA 146a, let-7e, and let-7g (involved in the regulation of inflammation) was determined by qPCR. The amount of secreted IL-6, IL-8, MIF, and GRO-alpha in cell culture supernatants was quantified by ELISA. Phosphorylation of NF-kappa B was assessed by Western blot and DNA damage was measured using the COMET assay. OLE decreased significantly released protein levels of IL-6 and IL-8, as well as mRNA expression of E-selectin in SAA-stimulated HCAEC and reduced MMP2 levels in unstimulated cells. Phosphorylation of NF-kappa B (p65) was upregulated in the presence of SAA, with OLE significantly attenuating this SAA-induced effect. OLE stabilized SAA-induced upregulation of microRNA-146a and let-7e in HCAEC, suggesting that OLE could fine-tune the SAA-driven activity of NF-kappa B by changing the microRNA networks in HCAEC. SAA induced DNA damage and worsened the oxidative DNA damage in HCAEC, whereas OLE protected HCAEC from SAA- and H2O2-driven DNA damage. OLE significantly attenuated certain pro-inflammatory and pro-adhesive responses and decreased DNA damage in HCAEC upon stimulation with SAA. The reversal of SAA-driven endothelial activation by OLE might contribute to its anti-inflammatory and anti-atherogenic effe

Published
2019

15. Obstetrical outcome and treatments in seronegative primary APS: data from European retrospective study.

Author

Abisror N, Nguyen Y, Marozio L, Esteve Valverde E, Udry S, Pleguezuelo DE, Billoir P, Mayer-Pickel K, Urbanski G, Zigon P, De Moreuil C, Hoxha A, Bezanahary H, Carbillon L, Kayem G, Bornes M, Yelnik C, Johanet C, Nicaise-Roland P, Lambert M, Salle V, Latino OJ, Hachulla E, Benedetto C, Bourrienne MC, Benhamou Y, Alijotas-Reig J, Fain O, and Mekinian A

Subjects
Antibodies, Antiphospholipid, Female, Humans, Pregnancy, Retrospective Studies, beta 2-Glycoprotein I, Antiphospholipid Syndrome diagnosis, Antiphospholipid Syndrome drug therapy, Antiphospholipid Syndrome epidemiology, Lupus Erythematosus, Systemic
Abstract

Objective: To compare characteristics, pregnancies and treatments during pregnancies of seronegative and seropositive antiphospholipid syndrome (APS), to analyse factors associated with obstetrical outcome., Patients and Methods: Inclusion criteria were: (1) thrombotic and/or obstetrical APS (Sydney criteria); (2) absence of conventional antiphospholipid antibodies (APL); (3) at least one persistent non-conventional APL among IgA anticardiolipin antibodies, IgA anti-B2GPI, anti-vimentin G/M, anti-annexin V G/M, anti-phosphatidylethanolamine G/M and anti-phosphatidylserine/prothrombin G/M antibodies. The exclusion criteria were: (1) systemic lupus erythematosus ( SLE) or SLE-like disease; and (2) other connective tissue disease., Results: A total of 187 women (mean 33±5 years) with seronegative APS were included from 14 centres in Austria, Spain, Italy, Slovenia and France and compared with 285 patients with seropositive APS. Seronegative APS has more obstetrical rather than thrombotic phenotypes, with only 6% of venous thrombosis in comparison to seropositive APS. Cumulative incidence of adverse obstetrical events was similar in seronegative and seropositive APS patients, although higher rates of intrauterine deaths (15% vs 5%; p=0.03), of preeclampsia (7% vs 16%, p=0.048) and lower live birth term (36±3 vs 38±3 weeks of gestation; p=0.04) were noted in seropositive APS. The cumulative incidence of adverse obstetrical events was significantly improved in treated versus untreated seronegative APS (log rank<0.05), whereas there was no difference between patients who received aspirin or aspirin-low-molecular weighted heparin combination., Conclusion: Several non-criteria APL can be detected in patients with clinical APS features without any conventional APL, with various rates. The detection of non-criteria APL and thus the diagnosis of seronegative APS could discuss the therapeutic management similar to seropositive APS, but well-designed controlled studies are necessary., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)

Published
2020
Full Text
View/download PDF

16. Comparison and evaluation of different methodologies and tests for detection of anti-dsDNA antibodies on 889 Slovenian patients' and blood donors' sera.

Author

Zigon P, Lakota K, Cucnik S, Svec T, Ambrozic A, Sodin-Semrl S, and Kveder T

Subjects
Adult, Antibodies, Antinuclear blood, Autoimmune Diseases blood, Autoimmune Diseases diagnosis, Autoimmune Diseases immunology, Blood Donors, Cross-Sectional Studies, DNA immunology, Enzyme-Linked Immunosorbent Assay methods, Enzyme-Linked Immunosorbent Assay standards, Female, Fluorescent Antibody Technique methods, Fluorescent Antibody Technique standards, Humans, Lupus Erythematosus, Systemic blood, Lupus Erythematosus, Systemic diagnosis, Lupus Erythematosus, Systemic immunology, Male, Middle Aged, Radioimmunoprecipitation Assay methods, Radioimmunoprecipitation Assay standards, Reference Values, Sensitivity and Specificity, Slovenia, Antibodies, Antinuclear analysis
Abstract

Aim: To evaluate four different commercially available assays for anti-double stranded DNA (dsDNA) detection and compare them with the in-house radioimmunoassay according to Farr (FARR-RIA) in order to select the optimal primary method for use in combination with FARR-RIA., Methods: Sera from 583 consecutive patients sent to our laboratory for routine diagnosis, 156 selected patients with autoimmune diseases (76 systemic lupus erythematosus [SLE] patients and 80 patients with other autoimmune diseases), and 150 blood donors were tested for anti-dsDNA antibodies with two enzyme-linked immunoassays (ELISA), two Crithidia luciliae immunofluorescence tests (CLIFT), and FARR-RIA. The specificities and sensitivities of the tests were calculated and compared., Results: FARR-RIA and CLIFT 2 showed the highest specificity for SLE (100%), with CLIFT 2 showing higher sensitivity (33% vs 47%). Both ELISAs showed higher sensitivities (>53%) than FARR-RIA but lower specificities (<93%), whereas CLIFT 1 showed the lowest overall agreement with FARR-RIA., Conclusion: CLIFT 2 was selected as the primary test for use in combination with FARR-RIA. The use of CLIFT 2 reduced the number of sera that needed to be tested by FARR-RIA, the time needed to report the results, and environmental toxicity, cancerogenicity, and radioactivity.

Published
2011
Full Text
View/download PDF

17. Epidemiology and diagnostics of primary Sjögren's syndrome.

Author

Rozman B, Novljan MP, Hocevar A, Ambrozic A, Zigon P, Kveder T, and Tomsic M

Subjects
Humans, Incidence, Prevalence, Slovenia epidemiology, Sjogren's Syndrome diagnosis, Sjogren's Syndrome epidemiology
Abstract

This review paper contains selected aspects of Sjögren's syndrome. It consists of epidemiology, ultrasound of salivary glands and antimuscarinic antibodies. The first part present studies aimed to determine the prevalence and the incidence of the disease with special emphasize on epidemiological studies performed in Slovenia. This is followed by the demonstration of the role of ultrasound of salivary glands in the diagnosis of Sjögren's syndrome and the value of antimuscarinic antibodies in global assesment of the secretory failure.

Published
2004

Catalog

Books, media, physical & digital resources
See catalog results